Metalloproteinases in Diabetics and Nondiabetics during Acute Coronary Syndromes and after 3 Months

REFERENCES

• Araki A., Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. Journal of Chromatography 1987; 422: 43–52
   PubMed Web of Science ®Google Scholar
• Brown D. L., Hibbs M. S., Kearney M., Loushin C., Isner J. M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125–2131
   PubMed Web of Science ®Google Scholar
• Carlyle W. C., Jacobson A. W., Judd D. L., Tian B., Chu C., Hauer K. M., Hartman M. M., McDonald K. M. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. Journal of Molecular and Cellular Cardiology 1997; 29: 2451–2463
   PubMed Web of Science ®Google Scholar
• Cheung P. Y., Sawicki G., Wozniak M., Wang W., Radomski M. W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833–1839
   PubMed Web of Science ®Google Scholar
• Clark I. M., Powell L. K., Wright J. K., Cawston T. E. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991; 11: 76–85
   PubMedGoogle Scholar
• Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica 1959; 17: 237–246
   Google Scholar
• Cooper M. E., Bonnet J., Oldfield M., Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: An overview. American Journal of Hypertension 2001; 14: 475–486
   PubMed Web of Science ®Google Scholar
• Creemers E. E., Cleutjens J. P., Smits J. F., Daemen M. J. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure?. Circulation Research 2001; 89: 201–210
   PubMed Web of Science ®Google Scholar
• Death A. K., Fisher E. J., McGrath K. C., Yue D. K. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263–269
   PubMed Web of Science ®Google Scholar
• Derosa G., Avanzini M. A., Geroldi D., Fogari R., Lorini R., De Silvestri A., Tinelli C., Rondini G., d'Annunzio G. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. Diabetes Care 2004; 27: 273–274
   PubMed Web of Science ®Google Scholar
• Derosa G., Cicero A. F., Scalise F., Avanzini M. A., Tinelli C., Piccinni M. N., Peros E., Geroldi D., Fogari E., D'Angelo A. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007; 14: 45–51
   PubMed Web of Science ®Google Scholar
• Derosa G., D'Angelo A., Ciccarelli L., Piccinni M. N., Pricolo F., Salvadeo S., Montagna L., Gravina A., Ferrari I., Galli S., Paniga S., Tinelli C., Cicero A. F. Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227–231
   PubMed Web of Science ®Google Scholar
• Dixon I. M., Ju H., Jassal D. S., Peterson D. J. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Molecular and Cellular Biochemistry 1996; 165: 31–45
   PubMed Web of Science ®Google Scholar
• Dollery C. M., McEwan J. R., Henney A. M. Matrix metalloproteinases and cardiovascular disease. Circulation Research 1995; 77: 863–868
   PubMed Web of Science ®Google Scholar
• Eckart R. E., Uyehara C. F., Shry E. A., Furgerson J. L., Krasuski R. A. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. Journal of Interventional Cardiology 2004; 17: 27–31
   PubMedGoogle Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999; 16: 716–730
   PubMed Web of Science ®Google Scholar
• Falk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation 1995; 92: 1137–1140
   Google Scholar
• Ferroni P., Basili S., Martini F., Cardarello C. M., Ceci F., Di Franco M., Bertazzoni G., Gazzaniga P. P., Alessandri C. Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation. Journal of Investigative Medicine 2003; 51: 295–300
   PubMed Web of Science ®Google Scholar
• Fox K. A. Management of acute coronary syndromes: an update. Heart 2004; 90: 698–706
   PubMed Web of Science ®Google Scholar
• Frangogiannis N. G., Smith C. W., Entman M. L. The inflammatory response in myocardial infarction. Cardiovascular Research 2002; 53: 31–47
   PubMed Web of Science ®Google Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Fujimoto N., Hosokawa N., Iwata K., Shinya T., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clinica Chimica Acta 1994; 231: 79–88
   PubMed Web of Science ®Google Scholar
• Fujimoto N., Mouri N., Iwata K., Ohuchi E., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clinica Chimica Acta 1993a; 221: 91–103
   PubMed Web of Science ®Google Scholar
• Fujimoto N., Zhang J., Iwata K., Shinya T., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinase-2 using monoclonal antibodies. Clinica Chimica Acta 1993b; 220: 31–45
   PubMed Web of Science ®Google Scholar
• Galis Z. S., Khatri J. J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad and the ugly. Circulation Research 2002; 90: 251–262
   PubMed Web of Science ®Google Scholar
• Havel R. J., Edr H. A., Bragdon J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 1955; 34: 1345–1353
   PubMed Web of Science ®Google Scholar
• Hayashidani S., Tsutsui H., Ikeuchi M., Shiomi T., Matsusaka H., Kubota T., Imanaka-Yoshida K., Itoh T., Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology 2003; 285: H1229–H1235
   PubMed Web of Science ®Google Scholar
• Heding L. G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260–266
   PubMed Web of Science ®Google Scholar
• Hirohata S., Kusachi S., Murakami M., Murakami T., Sano I., Watanabe T., Komatsubara I., Kondo J., Tsuji T. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997; 78: 278–284
   PubMed Web of Science ®Google Scholar
• Ikeda U., Shimada K. Matrix metalloproteinases and coronary artery diseases. Clinical Cardiology 2003; 26: 55–59
   PubMed Web of Science ®Google Scholar
• Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma level of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. American Heart Journal 2001; 141: 211–217
   PubMed Web of Science ®Google Scholar
• Jockers-Wretou E., Pfleiderer G. Quantitation of creatine kinase isoenzymes in human tissues and sera by an immunological method. Clinica Chimica Acta 1975; 58: 223–232
   PubMed Web of Science ®Google Scholar
• Jones C. B., Sane D. C., Herrington D. M. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovascular Research 2003; 59: 812–823
   PubMed Web of Science ®Google Scholar
• Jude B., Agraou B., McFaden E. P., Susen S., Bauters C., Lepelley P., Vanhaesbroucke C., Devos P., Cosson A., Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation 1994; 50: 1662–1668
   Google Scholar
• Judkins M. P. Selective coronary arteriography: A percutaneous transfemoral technique. Radiology 1967; 89: 815–824
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I., Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Annals of Epidemiology 1992; 2: 427–438
   PubMedGoogle Scholar
• Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., Sugi K., Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of American College of Cardiology 1998; 32: 368–372
   PubMed Web of Science ®Google Scholar
• Klose S., Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). Journal of Clinical Chemistry and Clinical Biochemistry 1978; 15: 121–130
   Google Scholar
• Larue C., Calzolari C., Bertinchant J. P., Leclercq F., Grolleau R., Pau B. Cardiac-specific immunoenzymometic assay of troponin I in the early phase of acute myocardial infarction. Clinical Chemistry 1993; 39: 972–979
   PubMed Web of Science ®Google Scholar
• Lim H., MacFadyen R. J., Lip G. Y.H. Diabetes, the renin-angiotensin aldosterone system and the heart. Archives of Internal Medicine 2004; 164: 1737–1748
   PubMed Web of Science ®Google Scholar
• Lindsey M., Wedin K., Brown M. D., Keller C., Evans A. J., Smolen J., Burns A. R., Rossen R. D., Michael L., Entman M. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181–2187
   PubMed Web of Science ®Google Scholar
• Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Scharnagl H., Hombach V., Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23: 283–288
   PubMed Web of Science ®Google Scholar
• Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Maxwell P. R., Timms P. M., Chandran S., Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabetic Medicine 2001; 18: 777–780
   PubMed Web of Science ®Google Scholar
• Muller-Bardorff M., Hallermayer K., Schroder A., Ebert C., Borgya A., Gerhardt W., Remppis A., Zehelein J., Katus H. A. Improved troponin T ELISA specific for cardiac troponin T isoform: Assay development and analytical and clinical validation. Clinical Chemistry 1997; 43: 458–466
   PubMed Web of Science ®Google Scholar
• Nagase H., Woessner J. F. Matrix metalloproteinases. Journal of Biological Chemistry 1999; 274: 21491–21494
   PubMed Web of Science ®Google Scholar
• Nakazawa T., Chiba T., Kaneko E., Yui K., Yoshida M., Shimokado K. Insulin signalling in arteries prevents smooth muscle apoptosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2005; 25: 760–765
   PubMed Web of Science ®Google Scholar
• Noda K., Ishida S., Inoue M., Obata K., Oguchi Y., Okada Y., Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Investigative Ophthalmology and Visual Science 2003; 44: 2163–2170
   PubMed Web of Science ®Google Scholar
• Peterson J. T., Li H., Dillon L., Bryant J. W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovascular Research 2000; 46: 307–315
   PubMed Web of Science ®Google Scholar
• Podesser B. K., Siwik D. A., Eberli F. R., Sam F., Ngoy S., Lambert J., Ngo K., Apstein C. S., Colucci W. S. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. American Journal of Physiology. Heart and Circulatory Physiology 2001; 280: H984–H991
   Web of Science ®Google Scholar
• Portik-Dobos V., Anstadt M. P., Hutchinson J., Bannan M., Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–3068
   PubMed Web of Science ®Google Scholar
• Rifai N., Tracy R. P., Ridker P. M. Clinical efficacy of an automated high-sensitivity c-reactive protein assay. Clinical Chemistry 1999; 45: 2136–2141
   PubMed Web of Science ®Google Scholar
• Rohde L. E., Aikawa M., Cheng G. C., Sukhova G., Solomon S. D., Libby P., Pfeffer J., Pfeffer M. A., Lee R. T. Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. Journal of The American College of Cardiology 1999; 33: 835–842
   PubMed Web of Science ®Google Scholar
• Scanu A. M., Scandian L. Lipoprotein (a): Structure, biology and clinical relevance. Advances in Internal Medicine 1991; 36: 249–270
   PubMedGoogle Scholar
• Shah P. K., Galis Z. S. Matrix metalloproteinase hypothesis of plaque rupture: Players keep piling up but questions remain. Circulation 2001; 104: 1878–1880
   PubMed Web of Science ®Google Scholar
• Sierevogel M. J., Pasterkamp G., de Kleijn D. P., Strauss B. H. Matrix metalloproteinases: A therapeutic target in cardiovascular disease. Current Pharmaceutical Design 2003; 9: 1033–1040
   PubMed Web of Science ®Google Scholar
• Toffaletti J., Blosser N., Hall T., Smith S., Tompkins D. An automated dry-slide enzymatic method evaluated for measurement of creatinine in serum. Clinical Chemistry 1983; 29: 684–687
   PubMed Web of Science ®Google Scholar
• Tyagi S. C., Kumar S. G., Haas S. J., Reddy H. K., Voelker D. J., Hayden M. R., Demmy T. L., Schmaltz R. A., Curtis J. J. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. Journal of Molecular and Cellular Cardiology 1996; 28: 1415–1428
   PubMed Web of Science ®Google Scholar
• Uemura S., Matsushita H., Li W., Glassford A. J., Asagami T., Lee K. H., Harrison D. G., Tsao P. S. Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. Circulation Research 2001; 88: 1291–1298
   PubMed Web of Science ®Google Scholar
• Uterman G., Weber W. Protein composition of lipoprotein (a). Journal of Clinical Investigation 1987; 80: 458–465
   PubMed Web of Science ®Google Scholar
• Vincenti M. P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase genes. Methods in Molecular Biology 2001; 151: 121–148
   PubMedGoogle Scholar
• Vranes D., Cooper M. E., Dilley R. J. Cellular mechanisms of diabetic vascular hypertrophy. Microvascular Research 1999; 57: 8–18
   PubMed Web of Science ®Google Scholar
• Wahlefeld A. W. Triglycerides determination after enzymatic hydrolysis. Methods of Enzymatic Analysis, 2nd ed., H. U. Bermeyer. Academic Press, New York 1974; 18–31
   Google Scholar
• Wilson E. M., Moainie S. L., Baskin J. M., Lowry A. S., Deschamps A. M., Mukherjee R., Guy T. S., St John-Sutton M. G., Gorman J. H., 3rd, Edmunds L. H., Jr., Gorman R. C., Spinale F. G. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003; 107: 2857–2863
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. WHO, Geneva June, 1997
   Google Scholar